Related Experiment Video
Updated: May 16, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study
I Muñoz-Repeto1, M J García, M Kamieniak
1Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Center, Madrid, Spain.
Histology and Histopathology
|December 13, 2012
Summary
This study analyzed familial ovarian cancers, finding BRCA1-associated tumors often show better outcomes and express more PR and P53. ERCC1 emerged as a potential marker for improved clinical results in hereditary ovarian cancer.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Familial epithelial ovarian cancers (FEOCs) and their specific pathological and immunohistochemical characteristics remain incompletely understood.
- Understanding these features is crucial for identifying diagnostic markers and guiding targeted therapies.
Purpose of the Study:
- To conduct a comprehensive immunohistochemical analysis of FEOCs from women with and without BRCA1 or BRCA2 mutations.
- To identify commonalities and distinctions among BRCA1, BRCA2, and non-BRCA1/2 familial ovarian carcinoma groups.
- To discover potential diagnostic markers for improved treatment selection.
Main Methods:
- Analysis of 73 familial primary ovarian carcinomas using tissue microarrays.
- Evaluation of the expression of 40 antibodies targeting various genetic pathways.
- Application of unsupervised cluster and survival analyses.
Main Results:
- Serous carcinomas were predominant across all familial groups.
- BRCA1 and BRCA2-associated ovarian carcinomas frequently presented as high-grade and advanced FIGO stage.
- BRCA1-associated carcinomas demonstrated better clinical evolution and higher expression of progesterone receptor (PR) and P53 compared to BRCA2 and non-BRCA1/2 groups.
- ERCC1 was identified as a potential prognostic marker for hereditary epithelial ovarian cancer.
Conclusions:
- Immunohistochemical profiling reveals distinct and shared features among different familial ovarian cancer subtypes.
- ERCC1 shows promise as a biomarker for predicting better clinical outcomes in hereditary epithelial ovarian cancer patients.
- Further research into these markers could refine diagnostic strategies and personalize treatment approaches for ovarian cancer.
